Weight Loss
Retatrutide
15mg
$160
Triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors. Research-grade retatrutide for metabolic optimization, body composition, and energy regulation.
- Tested by Freedom Diagnostics — independent US lab
- COA published with every lot
- Shipped from the US
For in-vitro research use only. Not for human or veterinary consumption, diagnostic, or therapeutic use.
Retatrutide is a next-generation triple incretin receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. In clinical trials it demonstrated superior weight loss outcomes compared to dual agonists, with Phase 2 data showing up to 24% reduction in body weight over 48 weeks. Its glucagon receptor activity provides additional energy expenditure benefits beyond GLP-1 alone.
Retatrutide activates GLP-1 receptors to suppress appetite and slow gastric emptying, GIP receptors to enhance insulin secretion and fat metabolism, and glucagon receptors to increase hepatic glucose output and thermogenesis. This multi-receptor engagement produces synergistic metabolic effects that exceed single or dual agonists in preclinical and early clinical data.
- Molecular Formula
- C₂₂₄H₃₅₆N₅₆O₆₈S₂
- Molecular Weight
- ~4.9 kDa
- Form
- Lyophilized peptide powder
- Solubility
- Soluble in bacteriostatic water
- Dosage Range
- 0.5–12mg weekly (research context)
- Plasma Half-Life
- ~6 days
- Bioavailability
- ~90% subcutaneous
Certificate of analysis
Independent third-party report for the lot you receive — identity and purity. Available on request with your order; we'll email it back the same business day.
Cold-chain when required
Temperature-sensitive peptides ship with insulation and coolant. Store as indicated on the vial. Stability notes included with the order.
For research only
Sold for in-vitro research and laboratory use. Not for human or veterinary consumption. We don't advise on protocols or dosing.
- [01]
Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial
Jastreboff A.M. et al. · New England Journal of Medicine · 2023
Retatrutide produced up to 24.2% mean weight reduction at 48 weeks, the highest reported for any obesity pharmacotherapy to date.
- [02]
Glucagon receptor agonism in metabolic disease
Day J.W. et al. · Nature Chemical Biology · 2009
Combined GLP-1/glucagon receptor activation produced greater fat loss and metabolic improvement than GLP-1 alone in preclinical models.
- [03]
GIP and GLP-1 receptor co-agonism for weight management
Finan B. et al. · Science Translational Medicine · 2013
Dual incretin receptor agonism demonstrated synergistic reductions in body weight and improved insulin sensitivity versus monotherapy.
